Aligos Therapeutics reports annual meeting vote results; directors elected, auditor ratified

Aligos Therapeutics, Inc.

Elected Class II directors: Thomas Woiwode (21.3M for, 4.2M withheld), Leonid Beigelman (21.5M for, 4.0M withheld), K. Peter Hirth (21.9M for, 3.6M withheld).
Ratification of Ernst & Young as auditor for FY2022 passed with 29.5M for, 90k against, 125 abstentions.
Broker non-votes of ~4.0M shares on director election.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.